Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cutaneous B-cell lymphoma. Classification and diagnostics].

E Geissinger1, P Adam, H K Müller-Hermelink

  • 1Institut für Pathologie, Universität Würzburg. geissinger@mail.uni-wuerzburg.de

Der Pathologe
|December 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.

The British journal of dermatology·2019
Same author

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

The British journal of dermatology·2018
Same author

The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.

Oncogene·2017
Same author

Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclass-switched immunoglobulin M immunophenotype.

The British journal of dermatology·2016
Same author

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.

Blood cancer journal·2016
Same journal

[Connective (tissue) pathology: What brings us together!]

Der Pathologe·2022
Same journal

[Giant cell-containing tumors of bone and differential diagnoses].

Der Pathologe·2022
Same journal

[Automation and application of robotics in the pathology laboratory].

Der Pathologe·2022
Same journal

[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].

Der Pathologe·2022
Same journal

[Artificial intelligence: a solution for the lack of pathologists?]

Der Pathologe·2022
Same journal

[Predictive immunocytochemistry in non-small cell lung carcinoma].

Der Pathologe·2022
See all related articles

Primary cutaneous B-cell lymphomas, including PCFCL, PCMZL, and PCLBCL, are classified by WHO-EORTC. Distinguishing these from systemic lymphomas requires staging, while pathologists aid in differentiating neoplastic from reactive lymphoproliferations.

Area of Science:

  • Dermatology
  • Hematology
  • Oncology

Context:

  • The WHO-EORTC classification identifies three primary cutaneous B-cell lymphomas: PCFCL, PCMZL, and PCLBCL (leg type).
  • PCFCL and PCMZL are indolent lymphomas with favorable prognoses.
  • PCLBCL (leg type) exhibits an aggressive clinical course.

Purpose:

  • To outline the classification of primary cutaneous B-cell lymphomas.
  • To emphasize the need for staging to differentiate primary cutaneous lymphomas from secondary skin involvement by systemic lymphomas.
  • To highlight the role of pathologists in distinguishing neoplastic from reactive cutaneous lymphoproliferations.

Summary:

  • Primary cutaneous B-cell lymphomas (PCFCL, PCMZL, PCLBCL) are distinct entities in the WHO-EORTC classification.

Related Experiment Videos

  • Accurate diagnosis necessitates staging to rule out secondary systemic lymphoma involvement.
  • Histological and immunohistochemical findings alone are often insufficient for definitive diagnosis.

    • Impact:

    • Improved diagnostic accuracy for cutaneous lymphomas.
    • Facilitation of appropriate staging and treatment strategies.
    • Enhanced understanding of the differential diagnosis in cutaneous lymphoproliferative disorders.